Low-dose aclarubicin in blastic transformation of essential thrombocythemia.
We attempted treatment with low-dose aclarubicin (ACR), a new anthracycline, in a 66-year-old man with blastic transformation of essential thrombocythemia (ET). Two courses of ACR (20 mg/day x 7 days) were given intravenously. He showed a good response to this therapy without severe side effects. He has since maintained a state of prolonged remission. These observations indicate that low-dose ACR may be beneficial for management of the blastic transformation of ET.
Asano
Y
Y
Munakata Medical Association Hospital, Fukuoka, Japan.
Naritomi
Y
Y
Kimura
H
H
Maeda
Y
Y
Kusaba
T
T
Yoshizawa
S
S
Shiraishi
G
G
D015250:Aclarubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy*; D006098:Granulocytes / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013920:Thrombocythemia, Essential / Q000188:drug therapy* / Q000473:pathology
D015250:Aclarubicin